Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial

New Antithrombotic Drugs

“…Abnormal liver function tests also were more common with elinogrel, but the abnormalities appeared to resolve over time, even if the drug was continued. 51,52 Elinogrel will soon undergo phase 3 evaluation in aspirin-treated patients with a history of MI within the past 6 months to 5 years. Such patients will be randomized to elinogrel (in one of two doses) or to placebo for approximately 29 months.…”

“…51 All patients received a 600-mg loading dose of clopidogrel followed by a second 300-mg loading dose of clopidogrel 4 h after the procedure. The primary outcome was major bleeding, which was infrequent and occurred at a rate with all doses of elinogrel that was similar to the rate with placebo.…”

Antiplatelet therapy in acute coronary syndromes

“…The safety and tolerability of adjunctive antiplatelet therapy with escalating intravenous doses of elinogrel in patients with STEMI undergoing primary PCI were evaluated in the pilot Phase IIA ERASE-MI trial [80]. It was found that treatment with a single intravenous bolus of elinogrel before primary PCI seemed to be feasible and well tolerated: the incidence of bleeding events was similar at all of the tested doses of elinogrel and placebo, and there were no differences in serious adverse events or ST-segment resolution.…”

Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease

“…118,119 The ongoing trial INtraveNous and Oral administration of elinogrel to eVAluate Tolerability and Efficacy in nonurgent PCI patients (INNOVATE-PCI). (INNOVATE-PCI; NCT00751231) is evaluating the efficacy and safety of three different doses of elinogrel (oral 50, 100 and 150 mg twice daily following an intravenous bolus) in patients undergoing non-urgent PCI.…”